- Home
- NKTR vs JRVR Comparison
NKTR vs JRVR Comparison
Compare NKTR & JRVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTR
- JRVR
- Stock Information
- Founded
- NKTR 1990
- JRVR 2002
- Country
- NKTR United States
- JRVR Bermuda
- Employees
- NKTR N/A
- JRVR N/A
- Industry
- NKTR Biotechnology: Pharmaceutical Preparations
- JRVR Property-Casualty Insurers
- Sector
- NKTR Health Care
- JRVR Finance
- Exchange
- NKTR Nasdaq
- JRVR Nasdaq
- Market Cap
- NKTR 108.3M
- JRVR 255.2M
- IPO Year
- NKTR 1994
- JRVR 2005
- Fundamental
- Price
- NKTR $24.25
- JRVR $5.59
- Analyst Decision
- NKTR Strong Buy
- JRVR Buy
- Analyst Count
- NKTR 6
- JRVR 4
- Target Price
- NKTR $81.67
- JRVR $6.06
- AVG Volume (30 Days)
- NKTR 4.8M
- JRVR 230.9K
- Earning Date
- NKTR 08-07-2025
- JRVR 08-04-2025
- Dividend Yield
- NKTR N/A
- JRVR 0.73%
- EPS Growth
- NKTR N/A
- JRVR N/A
- EPS
- NKTR N/A
- JRVR N/A
- Revenue
- NKTR $87,248,000.00
- JRVR $678,788,000.00
- Revenue This Year
- NKTR N/A
- JRVR $1.95
- Revenue Next Year
- NKTR N/A
- JRVR $6.80
- P/E Ratio
- NKTR N/A
- JRVR N/A
- Revenue Growth
- NKTR N/A
- JRVR N/A
- 52 Week Low
- NKTR $6.48
- JRVR $3.00
- 52 Week High
- NKTR $37.38
- JRVR $8.99
- Technical
- Relative Strength Index (RSI)
- NKTR 63.40
- JRVR 44.70
- Support Level
- NKTR $21.87
- JRVR $5.48
- Resistance Level
- NKTR $26.59
- JRVR $5.73
- Average True Range (ATR)
- NKTR 4.14
- JRVR 0.16
- MACD
- NKTR 0.01
- JRVR -0.06
- Stochastic Oscillator
- NKTR 54.77
- JRVR 12.39
About NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
About JRVR James River Group Holdings Ltd.
James River Group Holdings Ltd owns and operates a group of specialty insurance and reinsurance companies. It reports business into three segments. The Excess and Surplus Lines segment, which is the key revenue driver, offers commercial excess and surplus lines liability and excess property insurance products; The Specialty Admitted Insurance segment focuses on niche classes within the standard insurance markets with a primary focus on fronting business, where it retains a minority share of the risk and seek to earn fee income by allowing other carriers and producers to use its licensure, ratings, expertise and infrastructure, and the Corporate and other segment consists of the management and treasury activities of holding companies, and equity compensation for the group.